Related Experiment Video
Updated: Jun 3, 2026
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Stereotactic radiotherapy for hepatocellular carcinoma: report of a local single-centre experience
L C Chan1, Samuel K W Chiu, Stephen L Chan
1Department of Clinical Oncology, Prince of Wales Hospital, Shatin, Hong Kong. lc_chan@clo.cuhk.edu.hk
Objective:
To evaluate the efficacy and toxicities of stereotactic radiotherapy for unresectable hepatocellular carcinoma.
Design:
Retrospective study.
Setting:
Prince of Wales Hospital, Hong Kong.
Main Outcome Measures:
Treatment outcome and toxicities.
Patients:
During the period of 2000 to 2004, 16 patients with hepatocellular carcinoma treated with stereotactic radiotherapy were reviewed.
Results:
Of the 16 patients, 11 had assessable responses. For local control, there were two complete and three partial responses, five with stable disease and one with progressive disease, giving a local response rate of 45% and control rate of 91%. The median survival was 23 months. The 1-year and 3-year overall survival rates were 62% and 28%, respectively. The most frequent site of recurrence was intrahepatic but outside the irradiated field. Two patients with Child-Pugh B cirrhosis developed radiation-induced liver disease. No other grade 3/4 toxicities were recorded.
Conclusion:
Stereotactic radiotherapy gives high local control rates and has the potential to prolong survival in patients with hepatocellular carcinoma. It is safe and tolerable in Child-Pugh A patients.
